Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

El-Kattan

Showing results (111-120 of 115) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 115 results.
ACS Medicinal Chemistry Letters|December 1, 2015
Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic TreatmentMark Ammirati, Scott W Bagley, Samit K Bhattacharya, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2018
Delineating the role of cooperativity in the design of potent PROTACs for BTKAdelajda Zorba, Chuong Nguyen, Yingrong Xu, et al.
Journal of Medicinal Chemistry|August 19, 2020
Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver TargetingKim Huard, Aaron C Smith, Gregg Cappon, et al.
Bioorganic & Medicinal Chemistry Letters|December 25, 2010
Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distributionJeffrey A Pfefferkorn, John Litchfield, Richard Hutchings, et al.
Journal of Medicinal Chemistry|December 27, 2011
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitusJeffrey A Pfefferkorn, Angel Guzman-Perez, John Litchfield, et al.
Pageof 12

Showing results (111-120 of 115) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 115 results.
ACS Medicinal Chemistry Letters|December 1, 2015
Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic TreatmentMark Ammirati, Scott W Bagley, Samit K Bhattacharya, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2018
Delineating the role of cooperativity in the design of potent PROTACs for BTKAdelajda Zorba, Chuong Nguyen, Yingrong Xu, et al.
Journal of Medicinal Chemistry|August 19, 2020
Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver TargetingKim Huard, Aaron C Smith, Gregg Cappon, et al.
Bioorganic & Medicinal Chemistry Letters|December 25, 2010
Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distributionJeffrey A Pfefferkorn, John Litchfield, Richard Hutchings, et al.
Journal of Medicinal Chemistry|December 27, 2011
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitusJeffrey A Pfefferkorn, Angel Guzman-Perez, John Litchfield, et al.
Pageof 12